About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Eribulin - Breast Cancer Drug That Could Extend Lives of Breast Cancer Patients Approved

Font : A-A+

Highlights
  • Breast cancer, the most common cancer in women
  • 18.2% breast cancer deaths reported worldwide
  • Eribulin, life-extending drug for women with aggressive breast cancer

Eribulin - Breast Cancer Drug That Could Extend Lives of Breast Cancer Patients Approved

Women with breast cancer will now be able to benefit from Eribulin drug after the National Institute for Health and Care Excellence (NICE) agreed it should be made available across the NHS in England.

Eribulin received a European safety license more than five years ago, yet NICE has until now refused to make it routinely available on NHS. NICE has been criticized for sticking to a rigid formula for deciding whether the drug is cost-effective.

Advertisement


Updated draft guidance from NICE states that the drug should be made available to women who have locally advanced or metastatic breast cancer that has spread after two rounds of chemotherapy. The drug is given intravenously twice every 3 weeks.

The medication had previously been only available through the Cancer Drugs Fund.

Women with advanced breast cancer are expected to live only two years on average, a drug giving extra three months of life is considered valuable.
Advertisement

Working of Eribulin:

Eribulin, the chemotherapy drug works by stopping the cancer cells from spreading into new cancer cells and blocks the cancer growth. Common side effects associated with Eribulin include
  • Increased risk of getting infection
  • Tiredness and breathlessness
  • Fatigue
  • Hair thinning
  • Numbness
Breast Cancer Now chief executive Baroness Delyth Morgan said the drug will offer a "crucial" alternative to patients and its approval is positive news.

"It offers a crucial life-extending alternative for patients whose breast cancer has become resistant to other therapies, and for those with triple negative disease, who desperately lack treatment options," she said.

Professor Carole Longson, director of the centre for health technology evaluation at Nice, said: "The life expectancy of people for whom eribulin is licensed is short, and quality of life is very important."

She said: "But the real tests are still yet to come and we now eagerly await Nice's decision on the even more effective drugs being appraised, including Kadcyla.

NICE is currently reviewing all drugs funded to see whether they meet its strict cost-effectiveness thresholds.

Eribulin is one of the first to be moved from the temporary Cancer Drugs Fund use to routine NICE approval. 

  Reference
  1. Eribulin - General Information - (http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/cancer-drugs/eribulin/)
Source: Medindia

Citations   close

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sheela Philomena. (2016, November 03). Eribulin - Breast Cancer Drug That Could Extend Lives of Breast Cancer Patients Approved. Medindia. Retrieved on Sep 28, 2022 from https://www.medindia.net/news/healthwatch/eribulin-breast-cancer-drug-that-could-extend-lives-of-breast-cancer-patients-approved-164869-1.htm.

  • MLA

    Sheela Philomena. "Eribulin - Breast Cancer Drug That Could Extend Lives of Breast Cancer Patients Approved". Medindia. Sep 28, 2022. <https://www.medindia.net/news/healthwatch/eribulin-breast-cancer-drug-that-could-extend-lives-of-breast-cancer-patients-approved-164869-1.htm>.

  • Chicago

    Sheela Philomena. "Eribulin - Breast Cancer Drug That Could Extend Lives of Breast Cancer Patients Approved". Medindia. https://www.medindia.net/news/healthwatch/eribulin-breast-cancer-drug-that-could-extend-lives-of-breast-cancer-patients-approved-164869-1.htm. (accessed Sep 28, 2022).

  • Harvard

    Sheela Philomena. 2021. Eribulin - Breast Cancer Drug That Could Extend Lives of Breast Cancer Patients Approved. Medindia, viewed Sep 28, 2022, https://www.medindia.net/news/healthwatch/eribulin-breast-cancer-drug-that-could-extend-lives-of-breast-cancer-patients-approved-164869-1.htm.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Women and Cancer Drug Toxicity Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Signature Drug Toxicity Breast Cancer Facts Cancer Facts Cancer 

Most Popular on Medindia

Pregnancy Confirmation Calculator Hearing Loss Calculator Find a Hospital Loram (2 mg) (Lorazepam) Blood Pressure Calculator Iron Intake Calculator Daily Calorie Requirements Color Blindness Calculator Drug - Food Interactions Noscaphene (Noscapine)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Eribulin - Breast Cancer Drug That Could Extend Lives of Breast Cancer Patients Approved Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests